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Background: Gemcitabine must be administered at high doses to elicit the required therapeutic 
response because of its very short plasma half-life due to rapid metabolism. These high doses 
can have severe adverse effects.
Methods: In this study, polymeric microparticulate systems of gemcitabine were prepared using 
chitosan as a mucoadhesive polymer and Eudragit L100-55 as an enteric copolymer. The physi-
cochemical and biopharmaceutical properties of the resulting systems were then evaluated.
Results: There was no endothermic peak for gemcitabine in any of the polymeric gemcitabine 
microparticulate systems, suggesting that gemcitabine was bound to chitosan and Eudragit 
L100-55 and its crystallinity was changed into an amorphous form. The polymeric gemcit-
abine microparticulate system showed more than 80% release of gemcitabine in 30 minutes in 
simulated intestinal fluid. When mucin particles were incubated with gemcitabine polymeric 
microparticulates, the zeta potential of the mucin particles was increased to 1.57 mV , indicat-
ing that the polymeric gemcitabine microparticulates were attached to the mucin particles. 
Furthermore, the F53 polymeric gemcitabine microparticulates having 150 mg of chitosan 
showed a 3.8-fold increased uptake of gemcitabine into Caco-2 cells over 72 hours compared 
with gemcitabine solution alone.
Conclusion: Overall, these results suggest that polymeric gemcitabine microparticulate systems 
could be used as carriers to help oral absorption of gemcitabine.
Keywords: gemcitabine, polymeric microparticulates, mucoadhesive, enteric coating, cellular 
uptake, oral absorption
Introduction
Gemcitabine hydrochloride (2′,2′-difluoro-2′deoxycytidine hydrochloride) has 
therapeutic activity against a variety of solid malignancies, including colon, lung, 
pancreatic, breast, bladder and ovarian cancers.1–4 Once transported into the cell, 
gemcitabine must be phosphorylated by deoxycytidine kinase into its active form, 
5′-triphosphategemcitabine, which is incorporated into the DNA strand, halting 
elongation and causing cell death. Gemcitabine action also involves ribonucleotide 
reductase inhibition.5 However, gemcitabine (pKa 3.58) is rapidly metabolized in the 
blood, liver, and kidneys by cytidine deaminase into 2′,2′-difluoro-2′-deoxyuridine, an 
inactive derivative.6 Gemcitabine has a very short plasma half-life when administered 
intravenously, which is a major limitation of this anticancer compound.7 Recently, 
it has been postulated that continuous treatment with oral gemcitabine might be 
efficacious in human malignancies, and that oral dosing would be more convenient 
for patients than intravenous administration. Oral gemcitabine at low dose levels is 
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well tolerated and the main pattern of toxicity observed is 
gastrointestinal, whereas very little hematologic toxicity 
is observed, consistent with the low systemic exposure of 
gemcitabine.8 This is due to extensive first-pass metabolism 
to 2′,2′-difluoro-2′-deoxyuridine, which has been reported 
to be present mainly in the liver in humans and the kidney 
in mice.9 Thus, oral alternatives to intravenous gemcitabine 
administration can be investigated by strategies that facilitate 
enhanced intestinal absorption and circumvent metabolic 
inactivation by cytidine deaminase in the liver.10 Some 
type of protection for the anticancer drug, gemcitabine, 
which undergoes rapid metabolism in the plasma, must be 
developed. Recently, several approaches have been attempted 
to decrease deamination of gemcitabine to 2′,2′-difluoro-2′-
deoxyuridine, such as coupling a long chain fatty acid or an 
isoprenoid chain of squalene to the terminal amino group 
of gemcitabine, thereby protecting it from deamination by 
cytidine deaminase.11–13
On the other hand, colloidal drug delivery systems have 
received increasing attention as a possible means to obtain 
a higher therapeutic effect, lower toxicity, higher intestinal 
uptake, and protection from in vivo metabolism of incorpo-
rated drugs.1 From a structural point of view, nanoparticles 
comprise different systems, including nanospheres and 
nanocapsules.2
A high dose of gemcitabine is needed because rapid 
metabolism induces a very short half-life and low oral 
bioavailability (9.5%).14,15 In this work, we prepared p  olymeric 
particulate systems of gemcitabine using chitosan and 
polymethacrylate polymers to develop an oral delivery system 
and evaluated its physicochemical characteristics. Chitosan 
confers the polymeric particulate systems with mucoadhesion, 
and Eudragit L100-55, a polymethacrylate polymer, makes 
them enteric-coated to prevent gastric irritation.
Materials and methods
Materials
Gemcitabine hydrochloride was obtained from Dalian 
Wista Pharma Co, Ltd (Dalian, China). Polyvinyl alcohol 
(molecular weight 146–186,000), mannitol, and mucin were 
purchased from Sigma (Steinheim, Switzerland). Eudragit 
L100-55 [poly(methacrylic acid, ethyl acrylate) 1:1] was 
acquired from Degussa (Frankfurt, Germany). Chitosan 
(molecular weight 5–10,000) was purchased from Chitolife 
Co, Ltd (Pyungtaek, Korea). Sodium chloride was purchased 
from Samchun Chemical Co, Ltd (Pyungtaek). Dulbecco’s 
modified Eagle’s medium, fetal bovine serum, nonessential 
amino acid solution (10 mM, 100×), penicillin-streptomycin 
solution (10,000 U/mL penicillin and 10 mg/mL of strepto-
mycin), trypsin-EDTA solution (0.05% trypsin, 0.53 mM 
EDTA), N-(2-hydroxyethyl)piperazine-N′-2-ethane-sulfonic 
acid, and Hank’s Balanced Salt Solution with calcium and 
magnesium (without phenol red) were purchased from Gibco 
Laboratories (Cergy Pontoise, France). All other chemicals 
and solvents were of analytical reagent grade and used with-
out further purification.
Cell cultures
Caco-2 cells were purchased from the Korean Cell Line 
Bank (Seoul, Korea). Caco-2 cells (passage number 46–52) 
were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum, 1% nonessential 
amino acid solution, 100 units/mL penicillin, and 0.1 mg/mL 
streptomycin in a 5% CO2 atmosphere with 95% humidity 
in a 37°C incubator.
Preparation of polymeric gemcitabine 
microparticulates
Polymeric gemcitabine microparticulates were produced 
using a multiple emulsion method16,17 involving emulsification 
of an aqueous solution of the drug with a polymer solution 
in an organic solvent to form a w/o emulsion. This emulsion 
was further emulsified into a stirred aqueous processing 
medium containing an emulsion stabilizer to form a w/o/w 
emulsion, and the pH of each individual reaction solution 
was also measured. The organic solvent was removed over 
one hour by rotary evaporation (RE111 Rotavapor, Buchi, 
Switzerland). Briefly, 50 mg of gemcitabine was dissolved in 
1 mL of water and then mixed well with solubilized chitosan. 
At the same time, 500 mg of Eudragit L100-55 was dissolved 
in 10 mL of n-butanol. Gemcitabine including chitosan was 
slowly added to the organic Eudragit L100-55 solution and 
homogenized at 12,000 rpm for 10 minutes using a homog-
enizer (Ultra-Turrax T25, IkaWerk, Staufe, Germany) to 
form the primary emulsion (w1/o). The w1/o emulsion was 
further emulsified in 10 mL of a 1.0% aqueous solution of 
polyvinyl alcohol and 0.9% sodium chloride as an emulsion 
stabilizer at 5000 rpm for 10 minutes using a homogenizer, 
resulting in formation of a w1/o/w2 emulsion. These emul-
sions were rotary-evaporated to eliminate the organic phase, 
leaving hardened particles in an aqueous medium18 and then 
centrifuged at 3000 rpm for 10 minutes. Finally, 5 mL of 10% 
mannitol solution was added and the mixture was lyophilized. 
In this experiment, polymeric gemcitabine microparticulates 
containing chitosan were called F49–F53 according to the 
increase in amount of chitosan, ie, 10 mg, 25 mg, 50 mg, 
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100 mg, or 150 mg. The polymeric gemcitabine micropar-
ticulates without chitosan (F10) and the physical mixture 
of individual components of gemcitabine, chitosan, and 
Eudragit L100-55 were prepared as controls.
Assay of polymeric gemcitabine 
microparticulate
Polymeric gemcitabine microparticulates (10 mg) were dis-
solved in 10 mL of sodium phosphate buffer and methanol 
(9:1, v/v), sonicated for 10 minutes, and then centrifuged 
at 3000 rpm for 10 minutes. After centrifugation, 1 mL of 
supernatant was filtered through a membrane filter with a 
pore size of 0.2 µm and analyzed by high-pressure liquid 
chromatography. An Agilent 1100 liquid chromatography 
system with an autosampler and ultraviolet detector were 
used. A C18 column (4.6 × 250 mm, 5 µm particle size 
Eclipse, Agilent Technologies, Santa Clara, CA) was used. 
The flow rate of the mobile phase was 1.2 mL/minute and 
the detection wavelength was set to 275 nm. The mobile 
phase was a mixture of 97% monosodium phosphate buffer 
and 3% methanol. The column temperature was maintained 
at 35°C. The amount of gemcitabine in the polymeric 
microparticulates was determined by examining the drug 
loading and entrapment efficiency. The percentage drug 
loading was calculated by multiplying 100 by the ratio of 
total amount of drug extracted from the polymeric matrix of a 
known weight of microparticulates to the total weight of the 
microparticulates used before extraction. The encapsulation 
efficiency was calculated by multiplying 100 by the ratio of 
weight of drug present in a batch of microparticulates to the 
weight of drug used in the formulation.
Physicochemical characterization  
of polymeric gemcitabine microparticulates
The morphology and surface characteristics of the 
g  emcitabine polymeric microparticulates were examined by 
scanning electron microscopy (Model JEOL, JSM-7000F, 
Japan) operating at an accelerating voltage of 20 kV . The 
material was mounted on aluminum holders with carbon-
conducting glue and coated with a 20 nm gold layer in a 
Balzer’s MED 010 sputtering device. The particle size and 
zeta potential of the polymeric gemcitabine microparticu-
lates were determined by dynamic laser scattering (ELS-
8000   particle size analyzer, Otasuka Electronics, Japan). 
Differential scanning calorimetry was performed using a 
Perkin-Elmer DSC-7 instrument (SC S-650, Scinco, Korea) 
and Pyris software (version 5). The temperature axis and cell 
constant were calibrated using indium. A weighed sample 
(1.8 mg) of gemcitabine or polymeric gemcitabine micropar-
ticulates in a pin-holed aluminum pan was heated from 20°C 
to 400°C at a rate of 20°C per minute.
In vitro gemcitabine release profiles
A weighed amount of polymeric microparticulates (50 mg) 
containing 2.5 mg of gemcitabine based on entrapment 
efficiency data was dissolved in 100 mL of simulated gastric 
fluid or simulated intestinal fluid as the release medium using 
a paddle dissolution tester (Labfine Scientific Instruments, 
Anyang, Korea) based on Korean Pharmacopeia (KP) IX. 
At a predetermined time, 1 mL samples were withdrawn and 
replaced with the same volume of fresh medium adjusted to 
37°C. The samples were filtered through a membrane filter 
with a pore size of 0.2 µm and analyzed by high-pressure 
liquid chromatography.
Mucoadhesion test
We also evaluated the mucoadhesion forces of the polymeric 
gemcitabine microparticulates. The mucin particle method19 
is a simple mucoadhesion test in which commercial mucin 
particles are used. Mucoadhesion was examined by measuring 
the change in zeta potential of the mucin particles in a certain 
concentration of polymeric gemcitabine microparticulates. 
Briefly, mucin particles were suspended in distilled water at a 
concentration of 1% w/v and then dissolved in an appropriate 
amount of polymeric gemcitabine microparticulates in simu-
lated intestinal fluid at room temperature. After incubation 
for 12 hours, the zeta potential was measured.
Cytotoxicity assay
After a 72-hour incubation of the cells (70% confluent) 
with gemcitabine, cytotoxicity was determined by MTT 
assay according to the manufacturer’s protocol. Briefly, 
after incubation of cells with gemcitabine, MTT (3-(4,5-
  dimethylthiazol-2yl)-2,5-diphenyl-2H-tetrazolium bromide) 
was added to each well and incubated for 2 hours at 37°C. 
The crystals of viable cells were solubilized in isopropanol. 
Absorbance was determined at 570 nm in a microplate reader 
(Sunrise, Tecan, Austria). Cell viability (%) was represented 
with the (optical density [OD] of samples-treated cells 
divided by OD of cells incubated without samples) × 100.
Cellular uptake study
One day before the uptake experiments, Caco-2 cells (passage 
number 46–52) were seeded in 24-well plates at a density of 
5 × 105 cells/well. The cells were washed twice with serum-
free Dulbecco’s modified Eagle’s medium and then exposed 
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to either 10 mM of gemcitabine solution or polymeric 
g  emcitabine microparticulates for 72 hours. The cellular 
uptake studies were subsequently terminated by aspirating the 
medium and washing the cells three times with phosphate-
buffered saline. The cells were then lysed with 0.2 N NaOH, 
sonicated for 10 minutes, and then centrifuged at 3000 rpm 
for 10 minutes. The supernatant was filtered through a 
membrane filter with a pore size of 0.2 µm and analyzed by 
high-pressure liquid chromatography. The amount of protein 
in each sample was determined using the bicinchoninic acid 
method (Sigma, Steinheim, Switzerland).
Statistical analysis
The Student’s t-test  was  used  to  compare  groups. 
A P value ,0.05 was considered statistically significant.
Results and discussion
Surface morphology
The polymeric gemcitabine microparticulates using various 
amounts of chitosan showed a round morphology (  Figure 1). 
Some smooth spherical microparticulates were self-aggre-
gated and showed a sponge-like shape that might be attributed 
to the extrusion of aqueous internal droplets from the poly-
meric matrix to the external aqueous region during particle 
formation because of the relative instability of the quasi w/o 
emulsion.20–22 The particles were not only irregular balls with 
uneven surfaces, but also showed high surface aggregation 
forms. The amount of chitosan had no effect on the size and 
shape of the polymeric gemcitabine microparticulates.
Differential scanning calorimetry study
In order to assess the changes in the solid state of the poly-
meric gemcitabine microparticulates, differential scanning 
calorimetry analysis was performed. The thermal curve of 
gemcitabine was typical of a crystalline substance, with an 
endothermic peak at around 280.69°C (Figure 2). An endo-
thermic peak of gemcitabine was observed in the physical 
mixture, but there was no endothermic peak of gemcitabine 
in the polymeric gemcitabine microparticulates, suggesting 
that gemcitabine was chemically bound to chitosan and 
Eudragit L100-55, and subsequently its crystallinity had 
changed into the amorphous form. Furthermore, in the case 
of F10 without chitosan, there was no endothermic peak of 
gemcitabine. These results implied that Eudragit L100-55, 
which is a polyelectrolyte, played an important role in the 
transformation of gemcitabine by electrostatic interaction 
into an amorphous form.
Particle size and zeta potential
The particle size and zeta potential of polymeric gemcitabine 
microparticulates were evaluated to determine their physico-
chemical properties. In particular, as the amount of chitosan 
was increased from 10 mg to 150 mg, the zeta potential values 
for all the polymeric gemcitabine microparticulates except 
for F10 showed a tendency to increase (Figure 3). These 
data were consistent with those reported previously,23,24 sug-
gesting that gemcitabine and chitosan were electrostatically 
complexed during particle preparation and that the particles 
became aggregated. The pH of the gemcitabine aqueous 
solution was 2.1 and that of the gemcitabine aqueous solu-
tion and solubilized chitosan mixture was 2.4. After Eudragit 
L100-55 solution with a pH of 1.75 was added to the above 
mixture, the pH became 2.3. Subsequently, after polyvinyl 
alcohol solution having a pH of 5.3 was added to the w1/o 
emulsion, the pH of the final w1/o/w2 was 3.1. The zeta 
potential of gemcitabine itself was 0.95 ± 0.37 mV and that 
of chitosan was 6.1 ± 0.30 mV. The zeta potential of the 
polymeric gemcitabine microparticulates without chitosan 
CNU SEI 5.0 kV X5,000 1 µm WD 9.8 mm
CNU SEI 3.5 kV X5,000 1 µm WD 9.7 mm
CNU SEI 3.5 kV X3,000 1 µm WD 9.6 mm
CNU SEI 3.5 kV X10,000 1 µm WD 9.6 mm
CNU SEI 3.5 kV X1,500 10 µm WD 9.7 mm
CNU SEI 3.5 kV X3,000 1 µm WD 9.6 mm
F50 F51
F52 F53
F10 F49
Figure 1 Scanning electron micrographs of polymeric gemcitabine microparticulates.
Notes: F10 is polymeric gemcitabine microparticulates without chitosan and F49–
F53 is polymeric gemcitabine microparticulates according to the increase in chitosan 
amount, ie, 10 mg, 25 mg, 50 mg, 100 mg, or 150 mg.
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(F10) was −16.7 ± 1.82 mV, suggesting that gemcitabine 
and Eudragit L100-55 solutions were strongly repulsed, and 
subsequently showed the fewest microparticulates.
Assay of gemcitabine polymeric 
microparticulates
The concentration of gemcitabine in the polymeric micropar-
ticulates was quantified by measuring the yield, drug loading, 
and entrapment efficiency of gemcitabine. Fifty milligrams 
of polymeric gemcitabine microparticulates were assayed 
and entrapment efficiency was calculated. Poor entrap-
ment of alendronate sodium in poly(lactide-co-glycolide) 
  microspheres prepared by w/o/w emulsification has been 
reported previously.25 It was suggested that because alen-
dronate sodium was water-soluble (10 mg/mL), it had a 
tendency to escape to the external aqueous phase during 
microsphere formation and during washing of the formed 
microspheres. Therefore, drug hydrophilicity is a major 
challenge in the development of microspheres with high 
entrapment efficiency.22,26,27 It was found that when the drug 
loading was lowered, entrapment efficiency was also lowered. 
Except when no chitosan was present or a low chitosan 
dose of 10 mg was present in the polymeric microparticu-
lates, drug loading was determined to be 4.5%–5.8% and 
entrapment efficiency was determined to be 88.7%–97.9% 
(Table 1). However, there was no significant relationship 
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Figure 2 Differential scanning calorimetric thermograms of polymeric gemcitabine microparticulates.
Notes: The differential scanning calorimetric runs were conducted at 20°C–400°C and a rate of 20°C per minute. F10 is polymeric gemcitabine microparticulates without 
chitosan and F49–F53 is polymeric gemcitabine microparticulates according to the increase in chitosan amount, ie, 10 mg, 25 mg, 50 mg, 100 mg, or 150 mg.
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between amount of chitosan and drug loading and entrap-
ment efficiency. Jang et al28 reported that when the solvent 
evaporation rate was increased from 20 rpm to 280 rpm, 
the entrapment efficiency increased from 28.8% ± 3.3% to 
52.5% ± 6.8%, inferring that rapid membrane formation is 
an important phenomenon, preventing leakage of salmon cal-
citonin to the outer water phase. Also, the salmon calcitonin 
diffusion-delaying effect of high molecular weight polyvinyl 
alcohol (86,000) was greater than that of low molecular 
weight polyvinyl alcohol (66,000), which resulted in higher 
salmon calcitonin entrapment efficiency. In this study, 
the authors used high molecular weight polyvinyl alcohol 
(146,000–186,000) and increased the solvent evaporation rate 
to obtain higher entrapment efficiency (Table 1).
In vitro gemcitabine release profiles
There was less than 10% release of gemcitabine from the 
polymeric microparticulates after 2 hours in simulated gas-
tric fluid, due to enteric coating of the gemcitabine primary 
emulsion by Eudragit L100-55 (data not shown). In contrast, 
the polymeric gemcitabine microparticulates showed more 
than 80% release of gemcitabine in 30 minutes in simulated 
intestinal fluid (Figure 4). Rapid release of gemcitabine might 
occur due to fast dissolving of Eudragit L100-55 in simulated 
intestinal fluid. However, there was no   relationship between 
the percentage of gemcitabine released and the amount of 
chitosan.
Mucoadhesion test
The mucoadhesion of polymeric gemcitabine microparticulates 
was evaluated using commercially available porcine mucin 
particles in a simple mucoadhesion test. The surface properties 
of the mucin particles were expected to change due to adhesion 
of the polymeric gemcitabine microparticulates if the micropar-
ticulates had mucoadhesive properties. After the mucin particle 
suspensions were mixed with polymeric gemcitabine micropar-
ticulates dissolved in simulated intestinal fluid to remove the 
enteric coating of Eudragit L100-55, the zeta potential of the 
mucin particles was measured (Figure 5). This polymer has 
mucoadhesive properties due to its positive charges at neutral pH 
that enable electrostatic interaction with mucus or a negatively 
charged mucosal surface.19 The zeta potential of 1% mucin 
particle suspensions alone (pH 4.1) was −16.14 ± 2.75 mV 
and that of 1% mucin particle suspensions when incubated 
with 10 mg of chitosan was −1.17 ± 0.32 mV , suggesting that 
the zeta potential was increased due to adhesion of chitosan to 
the mucin particles. Therefore, the negative charge of the mucin 
particles appeared to be neutralized by the positive charge of 
chitosan absorbed onto their surface. When the amount of 
chitosan was increased from 10 mg to 150 mg, the zeta poten-
tial increased from −22.14 ± 2.50 mV to −1.22 ± 0.18 mV . 
As a reference, the zeta potential of F10 to mucin particles 
was −4.52 ± 1.67 mV .
Cytotoxicity and cellular uptake
Before the cellular uptake study of the polymeric gemcit-
abine microparticulates, a cytotoxicity study of gemcitabine 
against Caco-2 cells was performed to determine the IC50 of 
gemcitabine. Gemcitabine showed cytotoxicity at concentra-
tions above 50 mM in Caco-2 cells. The cell viability dropped 
Table 1 Formulation of polymeric gemcitabine microparticulates 
with chitosan
Formula  
number
Chitosan  
(mg)
Yield  
(%)
Drug  
loading (%)
Entrapment  
efficiency (%)
F10 0 86.4 1.8 33.4
F49 10 86.4 1.7 33.9
F50 25 91.7 5.8 93.7
F51 50 80.8 5.0 88.7
F52 100 100.8 4.5 97.9
F53 150 99.5 4.7 93.0
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Figure  4  In  vitro  release  profile  of  gemcitabine  from  polymeric  gemcitabine 
microparticulates in simulated intestinal juices.
Notes:  F49–F53  is  polymeric  gemcitabine  microparticulates  according  to  the 
increase of chitosan amount, ie, 10 mg, 25 mg, 50 mg, 100 mg, or 150 mg.
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suddenly at a gemcitabine concentration of 70–100 mM 
in Caco-2 cells, and subsequently the IC50 of gemcitabine 
against Caco-2 cells was determined to be 52.4 mM (Fig-
ure 6A). Therefore, gemcitabine solution or polymeric 
gemcitabine microparticulates corresponding to a gemcit-
abine 10 mM was added to each well and the percentage of 
gemcitabine uptake into Caco-2 cells was measured (Fig-
ure 6B). The gemcitabine solution showed 8.65% ± 3.64% 
intestinal cellular uptake of gemcitabine into Caco-2 cells 
over 72 hours because gemcitabine was released from the 
polymeric microparticulates in the cell culture medium (pH 
7.85). In particular, polymeric gemcitabine microparticulates 
containing 150 mg of chitosan (F53) showed a 3.8-fold 
increase in intestinal cellular uptake of gemcitabine into 
Caco-2 cells over 72 hours compared with uptake of gem-
citabine solution. As the amount of chitosan increased, the 
zeta potential values (Figure 3) and cellular uptake of gem-
citabine polymeric microparticulates also increased. It has 
previously been suggested that chitosan has mucoadhesive 
properties, as shown in Figure 5, and improves permeation 
of gemcitabine through Caco-2 cells.24 This is consistent with 
a report showing that microparticles prepared with chitosan 
and glyceryl monooleate exhibited mucoadhesive proper-
ties and a four-fold increase in cellular uptake.29 Chitosan 
is a hydrophilic, biodegradable, biocompatible, positively 
charged polysaccharide with low toxicity that in recent years 
has found applications in cosmetic, biotechnology, and drug 
delivery systems. The relationship between mucoadhesive-
ness of polymeric gemcitabine microparticulates in mucin 
particles with cellular uptake of gemcitabine from polymeric 
gemcitabine microparticulates into Caco-2 cells could not 
be explained because Caco-2 cells do not secrete mucin. 
Also, it could not be distinguished whether polymeric gem-
citabine microparticulates were actually internalized across 
Caco-2 cells or were bound onto the Caco-2 cell surface 
due to the mucoadhesive properties of chitosan. The authors 
recently reported that formulation of alendronate micropar-
ticles including chitosan showed a three-fold increase in 
uptake of alendronate into Caco-2 cells and caused a sig-
nificant 42.4% enhancement of alendronate permeability 
across Caco-2 monolayers.24 Therefore, further studies on the 
internalization of polymeric gemcitabine microparticulates 
and their absorption in vivo will be performed.
Conclusion
Polymeric microparticulate systems containing gemcit-
abine were prepared using various amounts of chitosan as a 
mucoadhesive polymer and Eudragit L100-55 as an enteric 
copolymer. F53 polymeric gemcitabine microparticulates 
showed a 3.8-fold increase in uptake of gemcitabine into 
Caco-2 cells over 72 hours compared with uptake of gemcit-
abine solution. Overall, these results suggest that polymeric 
microparticulate systems could improve the cellular uptake 
of gemcitabine.
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